HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

Summary

Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks. Treatment Duration: 8 weeks per group General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of juvenile idiopathic arthritis in this subject population. Number of Subjects: 66 (6 subjects in Cohort 1 and 60 subjects in Cohort 2) Indication: Juvenile Idiopathic Arthritis

Timeline

Start

2026-01

Primary completion

2026-01

Completion

2026-01

Outcome

Outcome not reported

Stopped (Enrollment): “In the time that the site has been active, there have been 0 patients enrolled despite our best efforts. It is clear that it is not feasible to conduct this study at this time; therefore, we have withdrawn this study.”

Drugs

Indications